Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...
and BioNTech will also get a share of gross profits from any future sales . If the vaccine works and is developed as rapidly as Pfizer and BioNTech hope, it could spell trouble for GSK ...
While generics may dominate due to cost advantages and meeting needs of a developing economy, there is a growing thrust ...
GSK’s current market share is around 9% with a nice gap separating it from the next competitor (7.7%) (IMS, YTD o8/2011). The Egyptian pharmaceutical market is considered one of the key emerging ...
Emily Field from Barclays and Lance Wilks share insights on how RFK Jr.'s influence could affect stocks in the pharmaceutical and healthcare sectors, including companies like GSK, Sanofi, and Novo ...
Company has Deloitte Haskins & Sells LLP as its auditors. As on 30-06-2024, the company has a total of 16.94 Crore shares outstanding.GSK Pharma Share Price Today is Rs. 2547.35 as on 12 Nov, 2024, 03 ...
WASHINGTON — Pharmaceutical industry giant GSK plans to depart the biotechnology industry’s largest trade group, the ...
Quant Mid Cap Fund - Direct (G) 225.06 8,29,800 2.52 Quant Large and Mid Cap Fund - Direct (IDCW) 61.30 2,26,000 1.65 Quant Large and Mid Cap Fund - Direct (B) 61.30 2,26,000 1.65 Quant Large and Mid ...
What was Glaxosmithkline Pharmaceuticals Ltd share price previously? Glaxosmithkline Pharmaceuticals Ltd share price was down by -1.93% from the previous closing price of ₹2,611.50. Who are ...
In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...
Prior to joining Gilead Canada, Paul most recently led Jazz Pharmaceuticals, where he built their Canadian organization over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback